Insider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $61,300.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $12.26, for a total transaction of $61,300.00. Following the completion of the sale, the director now owns 756,283 shares in the company, valued at $9,272,029.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cyrus Harmon also recently made the following trade(s):

• On Friday, June 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.77, for a total value of $215,400.00.
• On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.93, for a total value of $54,650.00.
• On Friday, May 31st, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.92, for a total value of $54,600.00.
• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $142,650.00.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $12.30 on Monday. Olema Pharmaceuticals, Inc. has a 12-month low of $7.78 and a 12-month high of $17.79. The firm has a 50-day moving average price of $11.06 and a 200-day moving average price of $11.86.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). As a group, analysts predict that Olema Pharmaceuticals, Inc. will post -2.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OLMA has been the subject of a number of recent research reports. The Goldman Sachs Group initiated coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Tuesday, June 4th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Olema Pharmaceuticals has an average rating of “Buy” and a consensus price target of $22.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in Olema Pharmaceuticals by 3.4% in the 1st quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock valued at $393,000 after buying an additional 1,132 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Olema Pharmaceuticals by 9.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,951 shares of the company’s stock valued at $224,000 after acquiring an additional 1,367 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Olema Pharmaceuticals by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after purchasing an additional 1,486 shares during the period. Public Employees Retirement System of Ohio bought a new position in Olema Pharmaceuticals in the third quarter worth approximately $35,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Olema Pharmaceuticals by 66.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,562 shares of the company’s stock worth $120,000 after purchasing an additional 4,221 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.